Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134903 | 0.85 | ADORA1 (0.39) | ADORA2AADORA1ADORA2BKMT2ACDK2 | |
| SCHEMBL6133471 | 0.83 | ADORA1 (0.50) | ADORA2AADORA1ADORA2BKMT2A | |
| SCHEMBL6133620 | 0.82 | ADORA1 (0.52) | ADORA2AADORA1ADORA2BKMT2A | |
| SCHEMBL6134537 | 0.82 | RPS6KA3 (0.48) | ADORA2AADORA1ADORA2BKMT2APDE10A | |
| SCHEMBL6134360 | 0.81 | LMNA (0.47) | ADORA2AADORA1ADORA2BKMT2A | |
| SCHEMBL6134083 | 0.79 | ADORA2A (0.65) | ADORA2AADORA1ADORA2BKMT2AADORA3 | |
| SCHEMBL6133989 | 0.79 | KMT2A (0.62) | ADORA2AADORA1ADORA2BKMT2APDE10A | |
| SCHEMBL6134665 | 0.79 | ADORA1 (0.39) | ADORA2AADORA1ADORA2BKMT2ACDK2 | |
| SCHEMBL6134043 | 0.78 | ADORA1 (0.53) | ADORA2AADORA1ADORA2BKMT2A | |
| SCHEMBL6133534 | 0.78 | ADORA1 (0.57) | ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885ADORA2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.